Germline HSD3B1 Genetics and Prostate Cancer Outcomes

Urology. 2020 Nov:145:13-21. doi: 10.1016/j.urology.2020.08.028. Epub 2020 Aug 28.

Abstract

Dihydrotestosterone synthesis in prostate cancer from adrenal DHEA/DHEA-sulfate requires enzymatic conversion in tumor tissues. 3β-hydroxysteroid dehydrogenase-1 is an absolutely necessary enzyme for such dihydrotestosterone synthesis and is encoded by the gene HSD3B1 which comes in 2 functional inherited forms described in 2013. The adrenal-permissive HSD3B1(1245C) allele allows for rapid dihydrotestosterone synthesis. The adrenal-restrictive HSD3B1(1245A) allele limits androgen synthesis. Studies from multiple cohorts show that adrenal-permissive allele inheritance confers worse outcomes and shorter survival after castration in low-volume prostate cancer and poor outcomes after abiraterone or enzalutamide treatment for castration-resistant prostate cancer. Here, we review the clinical data and implications.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Germ Cells
  • Humans
  • Male
  • Multienzyme Complexes / genetics*
  • Multienzyme Complexes / physiology
  • Progesterone Reductase / genetics*
  • Progesterone Reductase / physiology
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics*
  • Steroid Isomerases / genetics*
  • Steroid Isomerases / physiology
  • Treatment Outcome

Substances

  • 3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase
  • Androgen Antagonists
  • Multienzyme Complexes
  • Progesterone Reductase
  • Steroid Isomerases